Bayer, Sun Pharma sign marketing and distribution agreement for second brand of Finerenone in India
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Dapagliflozin and Saxagliptin Tablets (RLD Qtern) had estimated annual sales of US $5 million in the US
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Express Scripts to add Zepbound to National Preferred Formulary
This product will be manufactured by Indoco Remedies at their manufacturing facility located at Goa
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
This product will be manufactured at Lupin’s Pithampur facility in India
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
Subscribe To Our Newsletter & Stay Updated